Johnson & Johnson revealed that 21 abstracts highlighting both real‑world and clinical trial findings will be presented at the U.S. Psychiatric & Mental Health Congress (Psych Congress), scheduled for September 17‑21 in San Diego, California.
These presentations will draw on the Company’s neuropsychiatry portfolio, showcasing new data related to major depressive disorder (MDD), treatment‑resistant depression (TRD), and schizophrenia.
Key presentations points include:
- New data from a Phase 3 head-to-head study evaluating the safety and efficacy of seltorexant, an investigational first-in-class therapy, in combination with an oral antidepressant compared to adjunctive quetiapine extended release (XR) in MDD with insomnia symptoms (Poster 25).1
- Results from a post-hoc analysis of a Phase 3 study evaluating the efficacy of adjunctive CAPLYTA® in MDD patients who also met DSM-5 criteria for anxious distress (Poster 15).2
- Data from post-hoc analyses evaluating the effect of SPRAVATO® as a monotherapy on anhedonia symptoms and emotional blunting in adults with TRD (Posters 21,46).
Executive Statement
According to Bill Martin, Ph.D., Global Neuroscience Therapeutic Area Head, Johnson & Johnson Innovative Medicine, as the global leader in neuropsychiatry, they are harnessing decades of knowledge and expertise to redefine what's possible for people living with neuropsychiatric disorders. With patients at the center of everything they do, they are excited to present new clinical and real-world data from our leading portfolio, showcasing our commitment to advancing science and research to transform care and improve outcomes throughout the patient journey.
According to Tyrone Brewer, President, U.S. Neuroscience, Johnson & Johnson Innovative Medicine, a staggering one in eight people worldwide are living with a mental health disorder. At Johnson & Johnson, they are unwavering in our commitment to deliver a portfolio of differentiated and impactful solutions that confront neuroscience's toughest challenges. We remain steadfast in our pursuit of breakthroughs for patients who need them most.
